Patient-specific decisions about hormone replacement therapy in postmenopausal women

JAMA

Volumn 277, Issue 14, 1997, Pages 1140-1147

  Col, Nananda F ^a,d   Eckman, Mark H ^a   Karas, Richard H ^a   Pauker, Stephen G ^a   Goldberg, Robert J ^b   Ross, Elizabeth M ^a   Orr, Richard K ^b,c   Wong, John B ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Fallon Healthcare System   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; ENDOMETRIUM CANCER; FEMALE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030904631     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.14.1140     Document Type: Article

References (114)

1. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
2. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991; 265:1985-1990.
3. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-1593.
4. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitte D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304-313.
5. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
6. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
7. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110.
8. Lerman C, Kash K, Stefanek M. Younger women at increased risk for breast cancer: perceived risk, psychological well-being, and surveillance behavior. Monogr Natl Cancer Inst. 1994;16:171-176.
9. Black WC, Nease RF Jr, Tosteson ANA. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst. 1995;87:720-731.
10. Pilote L, Hlatky MA. Attitudes of women toward hormone therapy and prevention of heart disease. Am Heart J. 1995;129:1237-1238.
11. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993;329:247-256.
12. US Dept of Health and Human Services. Mortality, part B. In: Vital Statistics of the United States: Various Years Through 1991. Hyattsville, Md: National Center for Health Statistics; 1995; 2.
13. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst. 1993;85:892-897.
14. American Heart Association. Heart and Stroke Facts: 1996 Statistical Supplement. Dallas, Tex: American Heart Association; 1995.
15. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a worldwide projection. Osteoporos Int. 1992;2:285-289.
16. Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA. Race and sex differences in mortality following fracture of the hip. Am J Public Health. 1992;82:1147-1150.
17. Zubialde JP, Lawler F, Clemenson N. Estimated gains in life expectancy with use of postmenopausal estrogen therapy: a decision analysis. J Fam Pract. 1993;36:271-280.
18. Tosteson ANA, Weinstein MC. Cost-effectiveness of hormone replacement therapy after the menopause. Baillieres Clin Obstet Gynaecol. 1991; 5:943-959.
19. Gorsky RD, Koplan JP, Peterson HB, Thacker SB. Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol. 1994;83:161-166.
20. Office of Technology Assessment. Effectiveness and costs of osteoporosis screening and hormone replacement therapy. In: Cost-effectiveness Analysis. Washington, DC: Congress of the United States, Office of Technology Assessment; 1995; 1. Background paper.
21. Tosteson ANA, Rosenthal DI, Melton J, Weinstein MC. Cost-effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med. 1990;113:594-603.
22. Hillner BE, Hollenberg JP, Pauker SG. Postmenopausal estrogens in prevention of osteoporosis: benefit virtually without risk if cardiovascular effects are considered. Am J Med. 1986;80:1115-1127.
23. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
24. Pauker SG, Kassirer JP. Clinical decision analysis by personal computer. Arch Intern Med. 1981; 141:1831-1837.
25. Lau J, Kassirer JP, Pauker SG. DECISION MAKER 3.0: Improved decision analysis by personal computer. Med Decis Making. 1983;3:39-43.
26. Sonnenberg FA, Pauker SG. DECISION MAKER 6.0. In: MEDINFO 86, Proceedings of the Fifth Conference on Medical Informatics; October 26-30, 1986; Washington, DC. Part 2: 1152.
27. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-458.
28. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med. 1992;117: 1038-1041.
29. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1990;121:293-298.
30. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83:356-362.
31. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson IC. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996; 275:913-918.
32. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low-grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76:1197-1200.
33. Gail MK, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81: 1879-1886.
34. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women: Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767-773.
35. Farmer ME, White LR, Brody JA, Bailey KR. Race and sex differences in hip fracture incidence. Am J Public Health. 1984;74:1374-1380.
36. Fisher ES, Baron JA, Malenka DJ, et al. Hip fracture incidence and mortality in New England. Epidemiology. 1991;2:116-122.
37. National Cancer Institute. Surveillance, Epidemiology, and End Results: Incidence and Mortality Data, 1973-1977. Bethesda, Md: US Dept of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1981: Table 11F. National Cancer Institute monograph 57; NIH publication 81-2330:100.
38. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75-78.
39. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988;159:312-317.
40. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313: 1044-1049.
41. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208. Correction: JAMA. 1995;274:1676.
42. Falkeborn M, Persson I, Adomami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 1992;99:821-828.
43. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA. 1989;261:2095-2100.
44. Stampfer MJ, Grodstein F, Colditz GA, et al. Estrogen and estrogen/progestin and risk of cardiovascular disease: prospective data from the Nurses' Health Study. Am J Epidemiol 1995;14 (suppl):57.
45. Medical Research Council's General Practice Research Framework. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ. 1996;312:473-478.
46. Stanford TL, Weiss NS, Voight LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995;274:137-142.
47. Adami H-O, Persson I. Hormone replacement and breast cancer: a remaining controversy? JAMA. 1995;274:178-179.
48. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980;303:1195-1198.
49. Lafferty FW, Fiske ME. Postmenopausal estrogen replacement: a long-term cohort study. Am J Med. 1994;97:66-77.
50. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study. N Engl J Med. 1987;317:1169-1174.
51. Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med. 1981; 95:28-31.
52. Hutchinson TA, Polansky SM, Feinstein AR. Post-menopausal estrogens protect against fracture of hip and distal radius: a case-control study. Lancet. 1979;2:705-709.
53. Johnson RE, Specht EE. The risk of hip fracture in postmenopausal females with and without estrogen drug exposure. Am J Public Health. 1981; 71:138-144.
54. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985;102:319-324.
55. Kreiger N, Kelsey JL, Holford TR, O'Connor T. An epidemiologic study of hip fracture in postmenopausal women. Am J Epidemiol. 1982;116:141-148.
56. Williams AR, Weiss NS, Ure CL, Ballard J, Daling JR. Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women. Obstet Gynecol. 1982;60: 695-699.
57. Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture: a prospective, population-based cohort study. Ann Intern Med. 1990; 113:95-103.
58. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR, for the Study of Osteoporotic Fractures Research Group: estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;122:9-16.
59. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1996;276: 1389-1396.
60. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1996;275:370-375.
61. Speroff L, Rowan J, Symons J, Genant H, Wilborn W, for the CHART Study Group. The comparative effect on bone density, endometrium, and lipids of Continuous Hormones As Replacement Therapy (CHART study): a randomized controlled trial. JAMA. 1996;276:1397-1403.
62. Beck JR, Pauker SG. A convenient approximation of life expectancy (the 'DEALE'), I: validation of the method. Am J Med. 1982;73:883-888.
63. Beck JR, Pauker SG. A convenient approximation of life expectancy (the 'DEALE'), II: use in medical decision making. Am J Med. 1982;73:889-897.
64. Cupples LA, D'Agostino RB, Kiely D. Section 35, survival following initial cardiovascular events: thirty-year follow-up. In: Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: National Heart, Lung, and Blood Institute, US Dept of Health and Human Services, Public Health Service, National Institutes of Health; 1988. NIH publication 88-2969.
65. Schiffman J. Section 25, survival following certain cardiovascular events. In: Kannel WB, Gordon T, Garrison RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: National Heart, Lung, and Blood Institute, US Dept of Health and Human Services, Public Health Service, National Institutes of Health; 1970.
66. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med. 1990;150:2557-2562.
67. Miller BA, Ries LAG, Hankey BF, et al, eds. SEER Cancer Statistics Review: 1973-1990. Bethesda, Md: National Cancer Institute; 1993. NIH publication 93-2789.
68. Ries LG, Pollack ES, Young JL. Cancer patient survival: Surveillance, Epidemiology, and End Results program, 1973-79. J Natl Cancer Inst. 1983; 70:693-707.
69. Bergkvist L, Adami H-O, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol. 1989;130:221-228.
70. Strickland DM, Gambrell RD, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol. 1992;80:400-404.
71. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol. 1995;85:11-17.
72. Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA. Race and sex differences in mortality following fracture of the hip. Am J Public Health. 1992;82:1147-1150.
73. Katelaris AG, Cummings RG. Health status before and mortality after hip fracture. Am J Public Health. 1996;86:557-560.
74. Magaziner J, Simonsick EM, Kashner M, Hebel JR, Kenzora JE. Survival experience of aged hip fracture patients. Am J Public Health. 1989;79: 274-278.
75. Reno JH, Burlington H. Fractures of the hip: mortality survey. Am J Surg. 1958;95:581-592.
76. Alffram P-A. An epidemiologic study of cervical and trochanteric fractures of the femur in an urban population: analysis of 1,664 cases with special reference to etiologic factors. Acta Orthop Scand. 1964;65(suppl):1-109.
77. El Banna S, Raynal L, Gerebtzof A. Fractures of the hip in the elderly: therapeutic and medicosocial considerations. Arch Gerontol Geriatr. 1984; 3:311-319.
78. Elmerson S, Zetterberg C, Anderson GB. Tenyear survival after fractures of the proximal end of the femur. Gerontology. 1988;34:186-191.
79. Gordon PC. The probability of death following a fracture of the hip. Can Med Assoc J. 1971;105: 47-51.
80. Holmberg S, Conradi P, Kalen R, Thorngren KG. Mortality after cervical hip fracture: 3002 patients followed for 6 years. Acta Orthop Scand. 1986;57:8-11.
81. Sexson SB, Lehner JT. Factors affecting hip fracture mortality. J Orthop Trauma. 1987;1:298-305.
82. Kenzora JE, McCarthy RE, Lowell JD, Sledge CB. Hip fracture mortality: relation to age, treatment, preoperative illness, time of surgery, and complications. Clin Orthop. 1984;186:45-56.
83. White BL, Fisher WD, Laurin CA. Rate of mortality for elderly patients after fracture of the hip in the 1980's. J Bone Joint Surg Am. 1987;69: 1335-1340.
84. Dahl E. Mortality and life expectancy after hip fracture. Acta Orthop Scand. 1980;51:163-170.
85. Koval KJ, Zuckerman JD. Functional recovery after fracture of the hip. J Bone Joint Surg Am. 1994;76:751-758.
86. Zuckerman JD. Hip fracture. N Engl J Med. 1996;334:1519-1525.
87. Kuntz KM, Weinstein MC. Life expectancy biases in clinical decision modeling. Med Decis Making. 1995;15:158-169.
88. Kassirer JP, Moskowitz AJ, Lau J, Pauker SG. Decision analysis: a progress report. Ann Intern Med. 1987;106:275-291.
89. Kassirer JP, Pauker SG. The toss-up. N Engl J Med. 1981;305:1467-1469.
90. Posthuma WFM, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 1994;308:1268-1269.
91. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR, for the Study of Osteoporotic Fractures Research Group. Bone mineral density and risk of breast cancer in older women: the Study of Osteoporotic Fractures. JAMA. 1996;276:1404-1408.
92. Psaty BM, Heckbert SR, Atkins D, et al. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med. 1993;153:1421-1427.
93. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Community Health. 1989;43:173-178.
94. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal estrogen treatment and stroke: a prospective study. BMJ. 1988;297:519-522.
95. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users: results from a national cohort. Arch Intern Med. 1993;153:73-79.
96. Pfeffer RI, van Den Noorts. Estrogen use and stroke risk in postmenopausal women. Am J Epidemiol. 1976;103:445-456.
97. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995; 87:517-523.
98. Jacobs EJ, White E, Weiss NS. Exogenous hormones, reproductive history, and colon cancer. Cancer Causes Control. 1994;5:359-366.
99. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst. 1995;87:1067-1071.
100. Risch HA, Howe GR. Menopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epidemiol Biomarkers Prev. 1995;4:21-28.
101. MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies. Med J Aust. 1995;162:491-493.
102. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol. 1995;86:306-316.
103. Casper RF, Chapdelaine A. Estrogen and interrupted progestin: a new concept for menopausal hormone replacement therapy. Am J Obstet Gynecol. 1993;168:1188-1194.
104. Ryan PJ, Harrison R, Blake GM, Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol. 1992;99:325-328.
105. Doren M, Reuther G, Minne HW, Schneider HP. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol. 1995;173:1446-1451.
106. Salamone LM, Pressman AR, Seeley DG, Cauley JA. Estrogen replacement therapy: a survey of older women's attitudes. Arch Intern Med. 1996; 156:1293-1297.
107. Franklin C. Effectiveness and efficacy: which is which? Crit Care Med. 1994;22:1335-1336.
108. Medical Technology and Costs of the Medicare Program. Washington, DC: US Congress, Office of Technology Assessment; 1984. Publication OTA-H-227.
109. Tsevat J, Weinstein MC, Williams LW, Tosteson ANA, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation. 1991;83:1194-1201.
110. Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M. Cardiovascular Disease in Women: A Special Report. Dallas, Tex: American Heart Association; 1993. American Heart Association Scientific Statement.
111. Kassirer JP. Adding insult to injury: usurping patients' prerogatives. N Engl J Med. 1983;308: 898-901.
112. Elstein AS, Holzman GB, Ravit MM, et al. Comparison of physicians' decisions regarding estrogen replacement therapy for menopausal women and decisions derived from a decision analytic model. Am J Med. 1986;80:246-258.
113. Cohen BJ, Pauker SG. How do physicians weigh iatrogenic complications? J Gen Intern Med. 1994; 9:20-23.
114. Gura T. Estrogen: key player in heart disease among women. Science. 1995;269:771-773.